Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Use of telemedicine to improve access to clinical services and treatment for children with sickle cell disease
source: American Society of Pediatric Hematology/Oncology
year: 2016
authors: Kunal Sanghavi, Margaret Holtz, Kathleen Dempsey, Beth Vogel, Michele Caggana, Joann Bodurtha, Debra Cohen
summary/abstract:Patients with sickle cell disease (SCD) who live at long distances from their specialty care center can have difficulty with clinic visit compliance. The Children’s Hospital of Pittsburgh (CHP) and the New York Mid-Atlantic Consortium for Genetics and Newborn Screening Services (NYMAC), a federally funded regional collaborative, recognized the need for families and providers to improve access to clinical services for these patients.
Objectives: To continue to provide service utilizing telemedicine for pediatric patients with SCD. To host onsite telemedicine training to illustrate how Telehealth can improve accessibility to care, increase workforce capacity, and identify barriers to its implementation at CHP for pediatric hematologists in the NYMAC region (DC, DE, MD, NJ, NY, PA, VA, and WV).
Design/Method: Telemedicine infrastructure was established in a satellite clinic at both Erie and Johnstown in Western Pennsylvania for monthly telemedicine sessions. CHP Staff and CHP SCD providers completed the telemedicine training. Patient satisfaction surveys were administered following the telemedicine visit. Pediatric hematologists in the NYMAC region were invited to participate in an onsite training program at CHP.
Results: Nine pediatric patients were seen at the Erie clinic which yielded 73 completed telemedicine visits. Two pediatric patients were seen at the Johnstown clinic, yielding 7 completed telemedicine visits. Improvements with clinic access, hydroxyurea adherence, and patient satisfaction were noted as positive results of Telemedicine. The pilot at CHP in 2013 resulted in an increased proportion of patients receiving four annual clinic visits to 90%, as well as access to genetic counseling for SCD families. The proportion of patients receiving hydroxyurea increased to 50%. SCD telemedicine services saved patients/families crucial time and resources.
organization: New York Mid-Atlantic Consortium for Genetics and Newborn Screening Servicesread more
Related Content
-
Dental Health in Children with Sickle Cell DiseaseWhat is Sickle Cell Disease? Sickle Cel...
-
Phase 1 trial to test under-the-skin injection of sevuparin in sickle cell patientsModus Therapeutics is going to launch ...
-
James F. Casella, MDDr. James Casella is a professor of pedi...
-
Andrew D. Campbell, M.D.Dr. Campbell's distinguished training an...
-
Bioverativ and Sangamo announce FDA acceptance of IND application for gene-edited cell therapy BIVV003 to treat sick...Bioverativ Inc., a Sanofi company dedi...
-
Preclinical Data on Proprietary AKT Inhibitor, ARQ 092, Demonstrating Effectiveness in the Treatment of Sickle Cell ...ArQule, Inc. (Nasdaq: ARQL) today announ...
-
Patients frequently turning to cannabis to treat symptoms of sickle cell diseaseMedical cannabis use is relatively commo...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.